-The Business Standard Drugs are unaffordable, but price control is the wrong answer There is little doubt that medicines in India are too expensive for most of the population. For the poorest 20 per cent of Indians, the expenditure on medicines alone is 85 per cent of what they spend on their health, according to the National Sample Survey. A World Bank study on the subject found that just out-of-pocket medical costs...
More »SEARCH RESULT
Total Matching Records found : 765
No Country For Countrymen -Arun Sinha
-Outlook As the Manmohan Singh government makes evident its unfriendliness to villages, the nation hurtles towards disaster. It's a danger no one wants to face. Prime Minister Manmohan Singh has been trying for years to make us believe that agriculture is a vast marshland in which a huge population is stuck ankle- to neck-deep and it is his duty to rescue them. "Our salvation lies in moving people out of agriculture," he...
More »We trust indian manufacturing norms: USFDA -Divya Rajagopal
-The Economic Times MUMBAI: The United States Food and Drug Administration (USFDA), widely considered the world's most stringent regulatory authority, has said India's share in generic exports to the US over the years is an indication of the good manufacturing norms practised by Indian drugmakers. As the Ranbaxy scandal threatens to tarnish India's image as a hub of manufacturing world-class generic drugs, the statement, by USFDA's spokesman Chris Kelly in an...
More »It’s official: Indian economy slowed to a 10-year low of 5% in 2012-13
-The Times of India The Indian economy grew at its slowest pace in a decade in 2012-13, posing another fresh challenge for the UPA coalition to revive growth and boost sentiment ahead of the general elections next year. Data released by the Central Statistical Organization (CSO) on Friday showed that the economy grew 5% in 2012-13, compared to 6.2% expansion in the previous year. It was in line with the advanced...
More »Drugs, Ranbaxy and lies
-The Hindu Seven years after the first warning in June 2006 from the U.S. Food and Drug Administration (FDA) and five years after the Department of Justice initiated legal proceedings against the company, Ranbaxy is back in the news for the same wrong reasons. Last fortnight it pleaded guilty to felony charges in the U.S., admitting to selling adulterated drugs with intent to defraud, not reporting that its drugs failed...
More »
